For the Inventor, By the Inventor

Enter assignee name

Erytech Pharma

USPTO Granted Patents = 18

% Expired Patents = 11.1

CIPO Patents = 3

EPO Patents = 12

Trademarks = 2

Forward Citations = 137

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Yann Godfrin (15 out of 17 patents)

Fabien Gay (4 out of 4 patents)

Vanessa Bourgeaux (4 out of 4 patents)

4. Thomas Cortese (3 out of 3 patents)

5. Alice Banz (3 out of 3 patents)

6. Hélène Blois (2 out of 8 patents)

7. Pierre-Olivier Goineau (2 out of 2 patents)

8. Emmanuelle Dufour (1 out of 1 patent)

9. Manuel Blanc (1 out of 1 patent)

10. Aurélien Meyzaud (1 out of 1 patent)

11. Karine Aguera (1 out of 1 patent)

12. Willy Berlier (1 out of 1 patent)

13. Flavie Pouillot (1 out of 7 patents)

14. Jérôme Bailly (1 out of 1 patent)

15. Emmanuelle-Cécile Dufour (1 out of 1 patent)

18 patents: Sort by Forward Citations

1. 12280080 - Antibacterial composition and uses thereof (2025-04-21),

2. 11957724 - Phage therapy ofinfections (2024-04-16),

3. 11458170 - Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor (2022-10-04),

4. 11273210 - Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency (2022-03-15),

5. 11141468 - Method of treating a mammal, including human, against cancer using methionine and asparagine depletion (2021-10-12),

6. 10780151 - Composition and therapeutic anti-tumour vaccine (2020-09-22),

7. 10780126 - Pharmaceutical kit comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor (2020-09-22),

8. 10286008 - Method for stabilising suspensions of red blood cells encapsulating an active ingredient (2019-05-14),

9. 10273444 - Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes (2019-04-30),

10. 10046009 - Method of treatment using a pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and its cofactor (2018-08-14),

11. 9968663 - Erythrocytes containing arginine deiminase (2018-05-15),

12. 9950049 - Composition and therapeutic anti-tumour vaccine (2018-04-24),

13. 9580739 - Test for predicting neutralization of asparaginase activity (2017-02-28),

14. 9364504 - Compostition and therapeutic anti-tumour vaccine (2016-06-14),

15. 9125876 - Erythrocytes containing arginine deiminase (2015-09-08),

Erytech Pharma is a biopharmaceutical company based in Lyon, France, specializing in the development of innovative therapies for cancer and rare diseases. The company focuses on creating red blood cell-based drug delivery systems, leveraging its proprietary technology to encapsulate therapeutic agents. Erytech Pharma's research primarily targets the optimization of treatments for patients with unmet medical needs, aiming to enhance efficacy and reduce side effects through its unique approach to drug formulation and delivery.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

18 Patents

#22 in Lyon

#1,094 in France

#34,187 in the World

Erytech Pharma

Forward Citations = 137

17 inventors:

Yann Godfrin (15 out of 17 patents)

Fabien Gay (4 out of 4 patents)

Vanessa Bourgeaux (4 out of 4 patents)

4. Thomas Cortese (3 out of 3 patents)

5. Alice Banz (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…